← Back to headlines
Inventiva Reaches Final Patient Visit in NATiV3 Phase 3 MASH Trial
The pharmaceutical firm completed enrollment for its phase 3 clinical trial evaluating lanifibranor for metabolic dysfunction-associated steatohepatitis.
2 Sept, 20:05 — 2 Sept, 20:05
Related Stories
Genetically Modified Pig Kidney Functions in Human Patient for Record 271 Days
37m ago
New Zealand Approves MDMA Therapy for Severe PTSD Treatment
39m ago
UNICEF Report Reveals 20 Million Children Face Annual Online Sexual Exploitation
3h ago
Thousands Fall Ill After Eating Free School Meals in Indonesia
8h ago